Delayed handling of the poisoning incident at Somerset Medical Center

Somerset Medical Center’s delayed response to suspected patient poisonings exposed a dangerous divide between internal investigation and timely outside reporting. As patients suffered unexplained episodes associated with insulin and digoxin, hospital administrators sought more information before involving authorities; New Jersey Poison Control argued that the pattern required immediate action. The eventual report brought the cases to the state, but it came amid a dispute over institutional responsibility, the risk of further harm, and who had authority to investigate.

Emerging warnings and institutional control

The dispute took shape after Bruce Ruck of New Jersey Poison Control contacted Somerset Medical Center about the suspected incidents. When he called back the next day, the hospital’s head of pharmacy, Stuart Vigdor, told him that the administration had taken over the investigation and that hospital attorneys had asked him not to speak with outside agencies until the internal investigators had completed their work. Ruck warned that this placed Poison Control’s medical director in a difficult position, since the decision about contacting authorities could not be left solely to a pharmacy employee.

The hospital’s concerns were not based on a settled finding of criminal conduct. It was still seeking explanations for the incidents and weighing the consequences of a wider investigation. But from Poison Control’s perspective, waiting for certainty carried its own risk: if someone was deliberately harming patients, further delay could leave them exposed. The disagreement was therefore not simply over what had happened, but over whether the hospital could treat the matter as an internal inquiry while the possibility of continuing patient harm remained unresolved.

The conflict over reporting

On July 8, 2003, a conference call with Somerset administrators took place at nine in the morning after increasingly heated calls from Poison Control director Steven Marcus. Marcus told the hospital that if someone was purposely harming patients, the institution had a legal obligation to report it. Somerset risk manager Mary Lund and the administrators faced a choice they described as a tension between throwing the institution into chaos and protecting patients from further harm.

Somerset said it had been trying to investigate before making a judgment and had sought expert advice from Poison Control. Marcus countered that hospitals were poor at forensic investigation and that delays could allow a suspect to move on, making that person harder to locate. The disagreement went to the heart of the matter: Somerset treated further internal inquiry as a way to avoid a premature conclusion, while Marcus argued that the delay itself weakened the prospect of an effective investigation.

In a later conference call, Marcus again told the administrators that the incidents had to be reported to the state within twenty-four hours and that Somerset was already out of compliance. The hospital said it would not report the cases until it had mounted a thorough investigation. Marcus said he would report the matter personally if Somerset did not act, and warned that a report made by him would make the hospital’s position look worse. The call also marked an escalation in the dispute: Marcus told the administrators that their conversations had been recorded.

Marcus had, in fact, already contacted Eddy Bresnitz, the state epidemiologist and assistant commissioner of health, describing a cluster of illnesses that might be based on a criminal act. He also emailed assistant commissioner Amie Thornton about four untoward clinical events and Somerset’s unwillingness to report them before completing its own inquiry. Thus, the state-level escalation was underway even as the hospital continued to resist making its own report.

The eventual report and the hospital’s inquiry

A few hours after Marcus disclosed that the conversations had been recorded, Lund contacted the New Jersey Department of Health and Senior Services. Her report covered four incidents: Reverend Florian Gall and Jin Kyung Han had been associated with digoxin, while the other two involved insulin. It described steps Somerset had taken to check for manufacturer recalls and adverse drug interactions, verify that intravenous equipment and bedside monitors were working properly, and rerun laboratory tests to rule out lab error.

The hospital also tightened controls on digoxin, following its earlier controls on insulin, and made nurses more accountable for these commonly used medications. That change was a precaution: if the drugs were being used to harm patients, restricting access could make them harder to obtain. Somerset continued to regard human error as the likeliest explanation, reasoning that an innocent medication mistake ought to leave evidence in the records. Its review included the Pyxis MedStation 2000 drug system and Cerner patient charts, but the hospital had not found an innocent error in either system.

The report did not resolve the central uncertainty. Somerset acknowledged that something more sinister than a mistake remained possible, and Lund later told the state that human-resource issues were being evaluated and independent investigators were interviewing involved staff. On July 14, attorney Raymond J. Fleming came to the hospital, was briefed by Lund, and met with Charles Cullen. The progression from medication checks and chart review to staff interviews and a lawyer’s questioning showed that the internal inquiry was broadening even as the external reporting had been delayed.

Consequences for staff and the investigation

The unresolved investigation changed the atmosphere among nurses. Staff feared that police interviews might implicate them or damage their careers, while rumors about the deaths, insulin, and Cullen circulated across the unit. Amy Loughren was known as Cullen’s friend and had previously challenged a new insulin sign-out procedure. Her refusal to sign an electronic estimate of the insulin remaining in a vial had been an attempt to resist a protocol she considered inaccurate; she had also suspected that the change signaled an undisclosed danger involving patients. Now the same circumstances made her fear that suspicion might fall on her.

When investigators showed Loughren a Pyxis printout from the night Reverend Gall died, she recognized Cullen’s activity and could no longer dismiss the possibility that her friend had done something terrible. Recognition did not instantly resolve her personal conflict: she struggled to reconcile the record with the person she believed she knew. Asked to help, she weighed the risk to her job and the possibility that the detectives were wrong against her loyalty to Cullen. She ultimately assisted the investigation, feeling exposed and isolated from the institution she worked for, while sharing paperwork and helping investigators pursue records in Cerner.

The consequences also reached Gall’s family. Lucille Gall, a registered nurse who had spent long hours watching over her brother, learned that his blood had contained elevated digoxin. She understood the implication and objected that Somerset had recorded his death as natural without performing an autopsy. Her anger was sharpened by the fact that she had been both a devoted family caregiver and a nursing professional who could have understood the results. The delayed disclosure thus affected not only the investigation but also the family’s ability to understand the death and seek answers.

Aftermath and institutional significance

The wider consequences were not limited to Somerset. After Charles Cullen’s criminal proceedings, families of victims or potential victims sued the hospitals where he had worked. The New Jersey cases against hospitals were settled out of court, and the files and settlement terms were sealed; no criminal proceedings were brought against administrators at those hospitals.

The New Jersey State Legislature passed the Patient Safety Act in 2004, increasing hospitals’ responsibility to report serious preventable adverse events to the state health department. The following year, the Enhancement Act added reporting requirements concerning certain information about health-care professionals and required hospitals to retain records of complaints and disciplinary actions related to patient care for seven years. Thirty-five other states adopted these measures. The book notes an important limit: although compliant hospitals would not be liable for civil actions arising from their reports, there was no penalty or civil liability for hospitals that failed to comply.

Somerset’s handling of the incidents is therefore defined by a consequential contradiction. The hospital did eventually report the four cases, tighten medication controls, and pursue interviews and records; yet it initially placed its own investigation ahead of the prompt external reporting that Poison Control considered necessary. That delay left patient safety, forensic investigation, staff trust, and families’ access to answers entangled in a process whose central question was not only who had caused the harm, but how long an institution could wait before treating suspicion as a matter for authorities.